Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321932 | 0.82 | ADORA2A (0.40) | ADORA2A | |
| SCHEMBL30361253 | 0.82 | ADORA2A (0.40) | ADORA2A | |
| SCHEMBL12261736 | 0.74 | ADORA2A (0.63) | ADORA2A | |
| Pterine SCHEMBL4364328 | 0.74 | ADORA2A (0.63) | ADORA2A | |
| SCHEMBL687166 | 0.74 | ADORA2A (0.38) | ADORA2A | |
| SCHEMBL30570890 | 0.74 | ADORA2A (0.38) | ADORA2A | |
| SCHEMBL13596901 | 0.72 | ALDH1A1 (0.35) | — | |
| SCHEMBL686727 | 0.69 | PDE4A (0.38) | ADORA2A | |
| SCHEMBL7977529 | 0.69 | KDM4E (0.37) | — | |
| SCHEMBL8945215 | 0.69 | MMP2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0483426-A1 | Thiol heterocyclic deodorant composition and method of deodorization | THE PROCTER & GAMBLE COMPANY (US) | 1992-05-06 | — | — | EP | claimed |
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12269793-B2 | Affinity illudofulvene conjugates | AF CHEMICALS, LLC (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4257186-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4257186-A2 | AFFINITY MEDICANT CONJUGATES | AF Chemicals LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3129357-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230212113-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | AF Chemicals, LLC, (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210077425-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-10806708-B2 | Affinity medicant conjugate | AF CHEMICALS LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10285955-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2018-09-20 | — | — | US | disclosed |
| US-9980926-B1 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3129357-A2 | AFFINITY MEDICANT CONJUGATES | AF Chemicals LLC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9381178-B2 | Affinity medicant conjugate | AF CHEMICALS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160015658-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC | 2016-01-21 | — | — | US | disclosed |
| US-20150290152-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC | 2015-10-15 | — | — | US | disclosed |
| EP-0483426-A1 | Thiol heterocyclic deodorant composition and method of deodorization | THE PROCTER & GAMBLE COMPANY (US) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | ADORA2A 1973/4885 |
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | ADORA2A 1740/4885 |
| US-20230212113-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | ADORA2A 1973/4885 |
| US-20160015658-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ADORA2A 1740/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ADORA2A 1740/4885 |
| US-20150290152-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ADORA2A 1740/4885 |
| US-10285955-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | ADORA2A 1740/4885 |
| US-12269793-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | ADORA2A 1973/4885 |
| US-10806708-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | ADORA2A 1740/4885 |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ADORA2A 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.